1. Home
  2. ERAS vs SFIX Comparison

ERAS vs SFIX Comparison

Compare ERAS & SFIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • SFIX
  • Stock Information
  • Founded
  • ERAS 2018
  • SFIX 2011
  • Country
  • ERAS United States
  • SFIX United States
  • Employees
  • ERAS N/A
  • SFIX N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • SFIX Catalog/Specialty Distribution
  • Sector
  • ERAS Health Care
  • SFIX Consumer Discretionary
  • Exchange
  • ERAS Nasdaq
  • SFIX Nasdaq
  • Market Cap
  • ERAS 484.4M
  • SFIX 482.8M
  • IPO Year
  • ERAS 2021
  • SFIX 2017
  • Fundamental
  • Price
  • ERAS $1.41
  • SFIX $4.64
  • Analyst Decision
  • ERAS Strong Buy
  • SFIX Hold
  • Analyst Count
  • ERAS 6
  • SFIX 4
  • Target Price
  • ERAS $4.83
  • SFIX $5.67
  • AVG Volume (30 Days)
  • ERAS 852.4K
  • SFIX 2.2M
  • Earning Date
  • ERAS 08-11-2025
  • SFIX 09-23-2025
  • Dividend Yield
  • ERAS N/A
  • SFIX N/A
  • EPS Growth
  • ERAS N/A
  • SFIX N/A
  • EPS
  • ERAS N/A
  • SFIX N/A
  • Revenue
  • ERAS N/A
  • SFIX $1,275,494,000.00
  • Revenue This Year
  • ERAS N/A
  • SFIX N/A
  • Revenue Next Year
  • ERAS N/A
  • SFIX N/A
  • P/E Ratio
  • ERAS N/A
  • SFIX N/A
  • Revenue Growth
  • ERAS N/A
  • SFIX N/A
  • 52 Week Low
  • ERAS $1.01
  • SFIX $2.21
  • 52 Week High
  • ERAS $3.31
  • SFIX $6.99
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 40.59
  • SFIX 50.33
  • Support Level
  • ERAS $1.34
  • SFIX $4.39
  • Resistance Level
  • ERAS $1.81
  • SFIX $5.36
  • Average True Range (ATR)
  • ERAS 0.12
  • SFIX 0.26
  • MACD
  • ERAS -0.03
  • SFIX -0.04
  • Stochastic Oscillator
  • ERAS 7.45
  • SFIX 40.38

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About SFIX Stitch Fix Inc.

Stitch Fix Inc offers personal style services for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandise with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types, and price points including Women's, Petite, Maternity, Men's, and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry, and handbags and sells merchandise across various ranges of price points.

Share on Social Networks: